– CANADA, Halifax – IMV Inc. (Nasdaq: IMV | TSX: IMV), a clinical-stage company today announced the election of Michael Bailey to Chairman of its Board of Directors, effective May 1, 2022.
Mr. Bailey has served on the Board of Directors since 2020 and chairs the governance committee, as well as serving as a member of the audit and clinical governance committees.
“Michael has brought a connectivity in biotech and a depth of expertise in clinical strategy, business development and commercialization to the IMV Board. We are excited to leverage his knowledge and experience as we transition into late-stage clinical development and renew our focus on Business Development opportunities for our DPX platform,” said CEO, Andrew Hall.
About Michael P. Bailey
Mr. Bailey has more than 30 years of pharmaceutical industry experience, having been instrumental in the commercial planning and launch of several new medicines across multiple oncology indications. Most recently, he played a critical role in the approval of AVEO’s lead compound, FOTIVDA, a treatment targeting relapsed and refractory advanced renal cell carcinoma for patients who have failed at least two prior therapies. He joined AVEO as Chief Commercial Officer in 2010; then served as Chief Business Officer from 2013 until he was appointed CEO and member of their Board in 2015. Before joining AVEO, Mr. Bailey served as Chief Commercial Officer and Senior Vice President of Business Development at Synta Pharmaceuticals. Previously, he led ImClone Systems’ (now Eli Lilly) worldwide commercial organization. During his tenure at ImClone, he was responsible for all commercial aspects of the planning and launch of ERBITUX across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA and necitumumab. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and worldwide partnerships. Before joining ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., and was a key member of their global commercial partnership teams.
About IMV
IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform: the DPX technology. Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. IMV’s lead candidate, maveropepimut-S, delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers. MVP-S also delivers an innate immunity activator and a universal CD4 T cell helper peptide. These elements foster the maturation of antigen-presenting cells as well as robust activation of CD8 T cell effector and memory function. MVP-S treatment has been well-tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained survivin-specific anti-tumor immune response. MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma as well as ovarian, bladder, and breast cancers. IMV is also developing second immunotherapy leveraging the DPX immune delivery platform, DPX-SurMAGE. This dual-targeted immunotherapy combines antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously. A Phase 1 clinical trial in bladder cancer was initiated in early 2022.
For more information: https://www.imv-inc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.